A Phase I Study of HLX109 in Healthy Participants
brief summary
This study is a randomized, double-Blind, single ascending dose, phase I clinical study to evaluate safety, tolerability and pharmacokinetic profiles of HLX109 in healthy participants
detailed description
This first-in-human clinical trial of HLX109 is a randomized, double-blind, placebo-controlled, single ascending dose phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX109 in healthy adult participants. Each participant is expected to participate in the study for 112 days. The first 28 days constitute the screening period, followed by a study drug administration and an 84-day follow-up period.
official title
A Randomized, Double-Blind, Single Ascending Dose, Phase I Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetic Profiles of HLX109 in Healthy Participants